May 3, 2021

IQVIA’s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–IQVIA (NYSE: IQV) announced today that it will collaborate with Corium, Inc – a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies – to support the launch of AZSTARYS™, which was approved by the U.S. FDA on March 2, 2021. AZSTARYS is the first and only product containing a dexmethylphenidate (d-MPH) oral prodrug for the treatment of attention deficit hyperactivity


Leave Comment


Your Name *
Your Email *
Your Website
Comment *